Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program
Consun Pharmaceutical Group (HKG:1681) plans to grant share options of about 8.2 million shares, representing 10% of the company's total issued shares, according to a Tuesday filing on the Hong Kong b
康臣葯業:股東周年大會通告
康臣葯業:2023 年度報告
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Kangchen Pharmaceutical (1681.HK): Significant advantages in the field of nephrology, performance continues to grow rapidly
Key investment results continued to grow rapidly: Since the company went public in 2013, as of 2023, operating income CAGR was 16.3%, and net profit CAGR was 17.8%. The growth rate in the industry has clearly slowed or even declined
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Keep integrity, innovate, and go farway丨Understand Kangchen Pharmaceutical (1681.HK)'s 2023 performance in one picture
Recently, Kangchen Pharmaceutical (1681.HK), the market leader in proprietary Chinese medicines for nephropathy, announced the results for the year ended December 31, 2023. The following will show you the 2023 annual results of Kangson Pharmaceuticals through a chart.
CONSUN PHARMA To Go Ex-Dividend On June 11th, 2024 With 0.3 HKD Dividend Per Share
March 30th - $CONSUN PHARMA(01681.HK)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.3 HKD dividend per share on June 21st, 2024. The ex-divid
Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit
Consun Pharmaceutical Group (HKG:1681) posted a 2023 profit attributable to shareholders of 784.5 million yuan, or 0.98 yuan per share, up from 682.9 million yuan, or 0.86 yuan per share, a year earli
Conson Pharmaceutical (01681) proposes to adopt the 2024 share option plan
Zhitong Finance App News, Kangchen Pharmaceutical (01681) issued an announcement. The company adopted the 2013 share purchase plan on December 2, 2013. According to the terms of the 2013 Share Option Plan, unless otherwise terminated or amended, the 2013 Share Option Plan will be valid for 10 years from the date of its adoption and will expire on December 1, 2023. After the 2013 share option plan expires, no share options will be offered or granted. As of the date of this announcement, there were still 504.63,900 share options granted but not yet exercised in the 2013 share option plan. In view of the 2013 share option plan
Kangchen Pharmaceutical (01681.HK): Net profit increased by 14.9% in 2023 to reach $780 million with final interest of HK$0.3 per share
On March 28, Ge Longhui | Kangchen Pharmaceutical (01681.HK) announced that in 2023, the Group achieved sales revenue of about RMB 2.59 billion, an increase of about 10.7% over the previous year; profit attributable to the company's equity shareholders was approximately RMB 780 million, an increase of about 14.9% over the previous year. Basic and diluted earnings per share were approximately RMB 0.99 and RMB 0.98 respectively. The Board proposed a final dividend of HK$0.3 per share for the year 2023. Looking at the business segment, Kangchen Pharmaceutical's sales revenue in 2023 was about RMB 2.2 billion, an increase of about 1 percent over the previous year
CONSUN PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Kangchen Pharmaceutical (1681.HK): Continued rapid growth in the field of nephrology
Event: The company announced results. Revenue for the full year of 2023 was RMB 2,590 billion, up 10.7% year on year, gross profit of RMB 1.922 billion, up 9.0% year on year, gross margin of 74.2%, net profit of RMB 785 million
Conson Pharmaceutical (01681): Feng Zhongshi has been appointed as Chairman of the Nomination Committee
Kangchen Pharmaceutical (01681) announced that Su Yuanfu has resigned as an independent country due to his intention to invest more time in other private affairs...
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
No Data